Avidity Biosciences, Inc (RNAM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avidity Biosciences, Inc (RNAM) has a cash flow conversion efficiency ratio of -0.101x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-169.77 Million) by net assets ($1.69 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RNAM market cap for the company's overall valuation and market capitalisation.
Avidity Biosciences, Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Avidity Biosciences, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Avidity Biosciences, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avidity Biosciences, Inc ranked by their cash flow conversion efficiency. See Avidity Biosciences, Inc (RNAM) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
REXEL S.A. ADR EO 5
F:E7V0
|
N/A |
|
BIM Birlesik Magazalar AS
IS:BIMAS
|
0.125x |
|
CSPC PHARMACEUT.GR. ADR4
F:CVGU
|
N/A |
|
TFI International Inc
TO:TFII
|
0.093x |
|
VAT GROUP AG UNSP.ADR 10
F:19V0
|
N/A |
|
Huntington Ingalls Industries Inc
NYSE:HII
|
-0.006x |
|
The Indian Hotels Company Limited
NSE:INDHOTEL
|
0.043x |
|
Industrial Bank Of Korea
KO:024110
|
0.054x |
Annual Cash Flow Conversion Efficiency for Avidity Biosciences, Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Avidity Biosciences, Inc from 2018 to 2025. View current stock price of Avidity Biosciences, Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.69 Billion | $-650.44 Million | -0.385x | -82.43% |
| 2024-12-31 | $1.42 Billion | $-300.87 Million | -0.211x | +11.20% |
| 2023-12-31 | $500.76 Million | $-119.06 Million | -0.238x | -0.86% |
| 2022-12-31 | $578.08 Million | $-136.27 Million | -0.236x | +5.17% |
| 2021-12-31 | $381.43 Million | $-94.81 Million | -0.249x | -105.08% |
| 2020-12-31 | $306.22 Million | $-37.12 Million | -0.121x | -218.15% |
| 2019-12-31 | $-65.36 Million | $2.49 Million | -0.038x | -116.23% |
| 2018-12-31 | $-41.13 Million | $-9.65 Million | 0.235x | -- |
About Avidity Biosciences, Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in… Read more